Analysis of PARK2 gene exon rearrangements in Russian patients with sporadic Parkinson's disease

Movement Disorders

Volumn 27, Issue 1, 2012, Pages 139-143

  Semenova, Elena V ^a   Shadrina, Maria I ^a   Slominsky, Pyotr A ^a   Ivanova Smolenskaya, Irina A ^b   Bagyeva, Gulbakhar ^b   Illarioshkin, Sergei N ^b   Limborska, Svetlana A ^a  

^a INSTITUTE OF MOLECULAR GENETICS   (Russian Federation)

^b RESEARCH CENTER OF NEUROLOGY   (Russian Federation)

Author keywords

Deletion; Duplication; PARK2 exon rearrangements; Parkinson's disease

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DYSTONIA; EARLY ONSET PARKINSON DISEASE; EXON; FEMALE; GENE; GENE DELETION; GENE DUPLICATION; GENE MUTATION; GENE REARRANGEMENT; GENETIC ANALYSIS; GENETIC SCREENING; HUMAN; LATE ONSET PARKINSON DISEASE; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; ONSET AGE; PARK2 GENE; PARKINSON DISEASE; PRIORITY JOURNAL; RUSSIAN FEDERATION; SPORADIC PARKINSON DISEASE;

ADULT; AGED; EXONS; FEMALE; GENE REARRANGEMENT; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; RUSSIA; UBIQUITIN-PROTEIN LIGASES; YOUNG ADULT;

EID: 84855973029     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23901     Document Type: Article

References (27)

1. Lesage S, Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet 2009; 18( R1): R48-R59.
2. Nussbaum RL, Polymeropoulos MH. Genetics of Parkinson's disease. Hum Mol Genet 1997; 6: 1687-1691.
3. Shadrina MI, Slominsky PA, Limborska SA. Molecular mechanisms of pathogenesis of Parkinson's disease. Int Rev Cell Mol Biol 2010; 281: 229-266.
4. Bertoli-Avella AM, Giroud-Benitez JL, Akyol A, et al. Italian Parkinson Genetics Network. Novel parkin mutations detected in patients with early-onset Parkinson's disease. Mov Disord 2005; 20: 424-431.
5. Hedrich K, Marder K, Harris J, et al. Evaluation of 50 probands with early-onset Parkinson's disease for parkin mutations. Neurology 2002; 58: 1239-1246.
6. Periquet M, Latouche M, Lohmann E, et al. French Parkinson's Disease Genetics Study Group; European Consortium on Genetic Susceptibility in Parkinson's Disease. Parkin mutations are frequent in patients with isolated early-onset parkinsonism. Brain 2003; 126( Pt 6): 1271-1278.
7. Zagorovskaia TB, Illarioshkin SN, Slominskiǐ PA, et al. [Clinical and genetic analysis of juvenile parkinsonism in Russia]. Zh Nevrol Psikhiatr Im S S Korsakova 2004; 104: 66-72. [Russian]
8. Fahn S, Elton R, Members of the UPDRS Development Committee. Unified Parkinson's Disease rating scale. In: Fahn S, Marsden CD, Calne DB et al., eds. Recent developments in Parkinson's disease. Florham Park, NJ: Macmillan Health Care Information 1987; 2: 153-164.
9. Goetz CG, Poewe W, Rascol O, et al. The Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 2004; 19: 1020-1028.
10. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
11. Shadrina MI, Semenova EV, Slominsky PA, et al. Effective quantitative real-time polymerase chain reaction analysis of the parkin gene (PARK2) exon 1-12 dosage. BMC Med Genet 2007; 8: 6.
12. Biswas A, Gupta A, Naiya T, et al. Molecular pathogenesis of Parkinson's disease: Identification of mutations in the parkin gene in Indian patients. Parkinsonism Relat Disord 2006; 12: 420-426.
13. Mellick GD, Siebert GA, Fanayama M, et al. Screening PARK genes for mutations in early-onset Parkinson's disease patients from Queensland, Australia. Parkinsonism Relat Disord 2009; 15: 105-109.
14. Keyser RJ, Lombard D, Veikondis R, Carr J, Bardien S. Analysis of exon dosage using MLPA in South African Parkinson's disease patients. Neurogenetics 2010; 11: 305-312.
15. Wu RM, Bounds R, Lincoln S, et al. Parkin mutations and early-onset parkinsonism in a Taiwanese cohort. Arch Neurol 2005; 62: 82-87.
16. Choi JM, Woo MS, Ma HI, et al. Analysis of PARK genes in a Korean cohort of early-onset Parkinson disease. Neurogenetics 2008; 9: 263-269.
17. Wang Y, Clark LN, Louis ED, et al. Risk of Parkinson disease in carriers of parkin mutations: estimation using the kin-cohort method. Arch Neurol 2008; 65: 467-474.
18. Chaudhary S, Behari M, Dihana M, et al. Parkin mutations in familial and sporadic Parkinson's disease among Indians. Parkinsonism Relat Disord 2006; 12: 239-245.
19. Djarmati A, Hedrich K, Svetel M, et al. Detection of Parkin (PARK2) and DJ1 (PARK7) mutations in early-onset Parkinson disease: Parkin mutation frequency depends on ethnic origin of patients. Hum Mutat 2004; 23: 525.
20. Sironi F, Primignani P, Zini M, et al. Parkin analysis in early onset Parkinson's disease. Parkinsonism Relat Disord 2008; 14: 326-333.
21. Kann M, Jacobs H, Mohrmann K, et al. Role of parkin mutations in 111 community-based patients with early-onset parkinsonism. Ann Neurol 2002; 51: 621-625.
22. Slominskiǐ PA, Miloserdova OV, Popova SN, et al. [Analysis of deletion mutations in the PARK2 gene in idiopathic Parkinson's disease]. Genetika 2003; 39: 223-228. [Russian]
23. Kahle PJ, Haass C. How does parkin ligate ubiquitin to Parkinson's disease? EMBO Rep 2004; 5: 681-685.
24. Sun M, Latourelle JC, Wooten GF, et al. Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study. Arch Neurol 2006; 63: 826-832.
25. Lohmann E, Periquet M, Bonifati V, et al. French Parkinson's Disease Genetics Study Group; European Consortium on Genetic Susceptibility in Parkinson's Disease. How much phenotypic variation can be attributed to parkin genotype? Ann Neurol 2003; 54: 176-185.
26. Foroud T, Uniacke SK, Liu L, et al. Parkinson Study Group. Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease. Neurology 2003; 60: 796-801.
27. Klein C, Pramstaller PP, Kis B, et al. Parkin deletions in a family with adult-onset, tremor-dominant parkinsonism: expanding the phenotype. Ann Neurol 2000; 48: 65-71.